Interim Report January-June 2009 is published on August 5 2009 at approximately 2 PM (GMT+1) with conference call at 3 PM (GMT+1)

Interim Report January-June 2009 is published on August 5 2009 at approximately
2 PM (GMT+1) with conference call at 3 PM (GMT+1)

Västra Frölunda, Sweden, August 3 2009 
Artimplant publishes Interim Report January-June 2009 on August 5 2009 at
approximately 2 PM (GMT+1). The Interim Report is presented by CEO Hans Rosén
and CFO Lars-Johan Cederbrant in conference call on August 5 2009 at 3 PM
(GMT+1). 

The presentation will be in Swedish. 

Date: Wednesday August 5 2009 
Time: 3 PM Central European Time (GMT+1) 

Dial in numbers: 

Swedish participants: +46 (0)8 505 598 53 
UK participants: +44 (0)20 3043 2436 
US participants: +1 866 458 40 87 

A presentation in PDF format will be available on Artimplant's website
www.artimplant.com a couple of minutes before the conference call starts.

For further information, please contact:
Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information is available at www.artimplant.com. To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on August 3 2009 at 1:30 PM (GMT+1).